These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22307138)

  • 1. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
    Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
    Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
    Meza-Junco J; Chu QS; Christensen O; Rajagopalan P; Das S; Stefanyschyn R; Sawyer MB
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):1-4. PubMed ID: 19672597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
    Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
    Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
    Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
    Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
    Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
    Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
    Bins S; Lenting A; El Bouazzaoui S; van Doorn L; Oomen-de Hoop E; Eskens FA; van Schaik RH; Mathijssen RH
    Pharmacogenomics; 2016 Sep; 17(14):1483-90. PubMed ID: 27533851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms.
    Mori S; Terada K; Ueki Y
    Mod Rheumatol; 2012 Aug; 22(4):515-23. PubMed ID: 21993917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
    Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
    Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
    Marshall JC; Liang Y; Sahasrabudhe V; Tensfeldt T; Fediuk DJ; Zhou S; Krishna R; Dawra VK; Wood LS; Sweeney K
    J Clin Pharmacol; 2021 Sep; 61(9):1220-1231. PubMed ID: 33813736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
    Sandanaraj E; Jada SR; Shu X; Lim R; Lee SC; Zhou Q; Zhou S; Goh BC; Chowbay B
    Pharmacogenomics J; 2008 Jun; 8(3):174-85. PubMed ID: 17700594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
    Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
    PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
    Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie PI; Uchaipichat V; Stek M; Lange JM; Phanuphak P; Cooper DA; Udomuksorn W; Miners JO
    Pharmacogenet Genomics; 2006 May; 16(5):321-9. PubMed ID: 16609363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
    Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
    Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
    Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
    Gammal RS; Court MH; Haidar CE; Iwuchukwu OF; Gaur AH; Alvarellos M; Guillemette C; Lennox JL; Whirl-Carrillo M; Brummel SS; Ratain MJ; Klein TE; Schackman BR; Caudle KE; Haas DW;
    Clin Pharmacol Ther; 2016 Apr; 99(4):363-9. PubMed ID: 26417955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
    Culley CL; Kiang TK; Gilchrist SE; Ensom MH
    Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.
    Collins KS; Metzger IF; Gufford BT; Lu JB; Medeiros EB; Pratt VM; Skaar TC; Desta Z
    Drug Metab Dispos; 2020 Mar; 48(3):169-175. PubMed ID: 31888882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.